Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis.

NPJ Breast Cancer · 2023 · PMC10232579 · PMID 37258524

Europe PMC DOI

hedged sentences

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

borderline significantP = 0.053so close (0.05 < p ≤ 0.1)

Among HER2 positive patients, exploratory analysis of the NeoALTTO trial have demonstrated a borderline significant decreased pCR rate for overweight/obese patients with HR + /HER2+ breast cancer (OR = 0.55, P = 0.053), but not in HR-/HER2+ breast cancer (OR = 1.3, P = 0.331) 11 .

also in 11,409 other papers

did not reach statistical significanceno p-value reported

Overweight/obese patients are less likely to achieve pCR among postmenopausal and HER2 2+ populations, although in our study this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.